Eplerenone for the Treatment of Central Serous Chorioretinopathy

• Status: Completed
• Trial end date: 2015-05-01
• Target enrollment: 0
• Participant gender: All

Summary

To test the effect oral eplerenone versus placebo in patients with central serious chorioretinopathy .

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Wills Eye
• Collaborator: Mid Atlantic Retina
• Treatments: Eplerenone; Spironolactone

Criteria

Inclusion Criteria:

• Age 18 and over

• Ability to give written informed consent

• Sub-retinal fluid under fovea seen on OCT

• Diagnosis of central serous chorioretinopathy (CSCR): classification is at the discretion of the investigator, but general guidelines are

1. Acute- first episode or symptoms less than one month prior to presentation

2. Chronic- previously documented sub-foveal fluid, any prior treatment, symptoms for over 3 months, or <50% reduction in fluid thickness on OCT after 3 months.

Exclusion Criteria:

• Age under 18

• Impaired decision-making ability

• At initial laboratory screening serum potassium >5.5 milliequivalent (mEq)/L

• At initial laboratory screening serum creatinine >2 mg/dL in men and >1.8 mg/dL in women or decreased renal function by creatinine clearance less than 50 mL/min

• Absence of sub-foveal fluid

• Any patient with prior treatment for CSCR within 3 months of enrollment

• Patients taking potassium supplements or potassium-sparing diuretics spironolactone, amiloride, and triamterene and/or potent CYP3A4 (cytochrome) inhibitors (amifostine, cyclosporine, fluconazole, itraconazole, ketoconazole, mifepristone, posaconazole, potassium salts, rituximab, tacrolimus, voriconazole nefazodone, troleandomycin, clarithromycin, ritonavir, and nelfinavir)

• Women who are pregnant or are actively trying to conceive

• Patients with type 1 or type 2 diabetes